Roctavian Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improvements in gene delivery technologies, increasing clinical understanding of hemophilia genetics, early regulatory approvals for gene therapies, expansion of specialty treatment centers, rising patient enrollment in gene therapy trials.

The growth in the forecast period can be attributed to increasing investments in curative genetic therapies, growing demand for durable hemophilia treatments, expansion of personalized medicine frameworks, rising adoption of value-based reimbursement models, continued innovation in vector engineering. Major trends in the forecast period include increasing adoption of one-time gene therapy treatments, rising focus on long-term disease modification, growing use of advanced viral vector technologies, expansion of precision genetic diagnostics integration, enhanced monitoring of post-therapy outcomes.

The increasing prevalence of hemophilia is expected to drive the growth of the roctavian market going forward. Hemophilia is a genetic disorder that impairs proper blood clotting due to a deficiency in clotting factors, commonly managed with replacement therapy. Its prevalence is rising because of improved diagnosis, greater awareness, and genetic testing that identifies more cases. Roctavian treats hemophilia A through a one-time gene therapy infusion, enabling the body to produce its own Factor VIII, reducing bleeding episodes and the need for ongoing clotting factor treatments. For instance, in October 2025, according to the World Federation of Hemophilia, a Canada-based non-profit organization, global identification of people with hemophilia increased by 6%, von Willebrand disease by 6%, and other inherited bleeding disorders by 9%. Therefore, the rising prevalence of hemophilia is driving the growth of the roctavian market.

The rising healthcare investments are expected to support the growth of the roctavian market going forward. Healthcare investments refer to the allocation of capital into sectors such as pharmaceuticals, medical devices, and digital health to promote innovation and growth. The increase in healthcare investments is driven by aging populations, technological advancements, and the rising burden of chronic diseases. Investments in roctavian support research, clinical trials, regulatory approvals, manufacturing, and market access strategies to ensure broad availability and effective treatment. For instance, in November 2025, the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental organization, reported that in 2023, public sources financed an average of 72% of healthcare spending in OECD countries. Therefore, the growth in healthcare investments is driving the expansion of the roctavian market.

Major companies in the roctavian market are focusing on developing innovative solutions, such as advanced gene therapies, to meet the growing demand for long-term, infusion-free treatment options for severe hemophilia A. Gene therapy delivers functional genetic material into patients’ cells, enabling them to produce essential proteins that traditional factor-replacement therapies supply externally. For instance, in June 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology company, received FDA approval for Roctavian, a gene therapy for adults with severe hemophilia A. Roctavian uses an adeno-associated viral vector to deliver a functional copy of the Factor VIII gene, allowing the body to produce its own clotting protein. It significantly reduces bleeding episodes, decreases reliance on regular prophylactic infusions, and provides durable therapeutic benefits. The approval was supported by the GENEr8-1 trial, which demonstrated substantial reductions in annualized bleeding rates, representing a major shift from frequent infusions to a single-treatment approach.

Major companies operating in the roctavian market are BioMarin Pharmaceutical Inc.

North America was the largest region in the roctavian market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roctavian market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the roctavian market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the roctavian market by increasing costs of imported viral vectors, bioprocessing equipment, single-use bioreactors, and quality control instruments essential for gene therapy manufacturing. North America and Europe are most affected due to dependence on specialized cross-border biotech supply chains, while Asia-Pacific faces higher costs for technology transfer and contract manufacturing services. These tariffs are increasing therapy development and commercialization expenses, contributing to high upfront treatment pricing. At the same time, they are encouraging domestic biomanufacturing investments, regional gene therapy hubs, and localized production capabilities that support long-term scalability and supply security.

The roctavian market research report is one of a series of new reports that provides roctavian market statistics, including roctavian industry global market size, regional shares, competitors with a roctavian market share, detailed roctavian market segments, market trends and opportunities, and any further data you may need to thrive in the roctavian industry. This roctavian market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Roctavian is a gene therapy designed to treat hemophilia A, a genetic disorder caused by a deficiency of clotting factor VIII. The therapy delivers a functional copy of the factor VIII gene, allowing the body to produce the clotting factor naturally, potentially providing long-term or permanent relief from the condition.

The primary clinical indications for Roctavian include severe hemophilia A, prophylactic therapy, patients without factor VIII inhibitors, and patients with neutralizing antibodies to AAV5. Severe hemophilia A is a genetic disorder characterized by very low or absent levels of clotting factor VIII, which is essential for proper blood clotting. The therapy is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, specialty clinics, homecare providers, and research institutions.

The roctavian market consists of sales of coagulation factor VIII products, immunosuppressive medications, and recombinant factor IX products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.